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Abstract
Current work in elucidating relationships between diseases has largely been based on pre-existing knowledge of disease
genes. Consequently, these studies are limited in their discovery of new and unknown disease relationships. We present the
first quantitative framework to compare and contrast diseases by an integrated analysis of disease-related mRNA expression
data and the human protein interaction network. We identified 4,620 functional modules in the human protein network and
provided a quantitative metric to record their responses in 54 diseases leading to 138 significant similarities between
diseases. Fourteen of the significant disease correlations also shared common drugs, supporting the hypothesis that similar
diseases can be treated by the same drugs, allowing us to make predictions for new uses of existing drugs. Finally, we also
identified 59 modules that were dysregulated in at least half of the diseases, representing a common disease-state
‘‘signature’’. These modules were significantly enriched for genes that are known to be drug targets. Interestingly, drugs
known to target these genes/proteins are already known to treat significantly more diseases than drugs targeting other
genes/proteins, highlighting the importance of these core modules as prime therapeutic opportunities.
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Introduction
Our understanding of the human disease state is incomplete
without the knowledge of how various diseases relate to each
other. Relationships between diseases have been used to gain
insights into the etiology and pathogenesis of similar diseases [1].
Study of disease similarities has also led to the discovery of new
causal genes for diseases [2,3]. Moreover, similarities between
biological concepts such as genes have been used successfully in
gene function prediction [4]. However, most of the early work on
finding disease-similarity has been limited to studying the clinical
phenotypes of the diseases. For instance, similarities in disease
symptoms and pathological results have been used to ascertain
similarities between Alzheimer’s disease and vascular dementia
[1]. These methods are not quantitative and cannot be used to
compare the relative similarities between diseases. More recently,
scientists have been able to explore the genetic similarity between
diseases because of the availability of large-scale knowledge-bases
such as the Online Mendelian Inheritance in Man (OMIM) [5]. In
2007, Goh and colleagues created the first ‘‘Diseasome’’, a
network of human diseases [6]. This network consisted of human
diseases/disorders as nodes and two diseases were joined by a link
if they shared known disease genes (data obtained from OMIM).
Van Driel et al. [7] inferred disease-disease associations by an
automated text mining of OMIM descriptions. Liu et al. [8] mined
for disease etiologies from the Medical Subject Headings (MESH)
[9] vocabulary and used it to reveal similarities between diseases.
Although the above studies provided comprehensive views of
disease interrelationships, they were mainly studying monogenic
disorders and generally ignored the effect of the environment on
these and other, more complex, diseases. They also relied heavily
on information that is already known, such as known disease genes
or known pathways. As a result, they were limited in their ability to
uncover hitherto unknown relations between diseases.
Advances in high-throughput molecular assay technologies,
accompanied by declining per-sample costs, have given rise to
numerous public repositories of biomolecular data such as mRNA
expression profiles and protein interaction networks. In particular,
the availability of these datasets for many different diseases
presents a ripe opportunity to use data-driven approaches to
advance our current knowledge of disease relationships in a
systematic way. As a matter of fact, very recently, Hu and Agarwal
[10] presented an approach to determine disease relationships
using only gene expression data. In order to obtain the disease
PLoS Computational Biology | www.ploscompbiol.org 1 February 2010 | Volume 6 | Issue 2 | e1000662correlations, the authors excluded genes which don’t change
meaningfully using an arbitrary threshold. They also did not take
advantage of the plethora of protein interaction data available for
the human system. Protein networks represent the physical
processes taking place inside a cell and are essential to acquire a
complete understanding of any biological condition such as
disease.
Therefore, just as sequencing of genomes has enabled the
reorganization of many species and provided quantitative metrics
to appreciate their relationships, we believe an integrated
approach combining both mRNA expression and protein
interaction data will provide us a quantitative way to assess the
correlation between diseases. Here, we present the first such
systematic and integrated approach to explore the architecture of
human diseases. In particular, we identified 4,620 functional
modules analogous to important complexes and pathways in the
human protein network and recorded how they varied in each of
the 54 diseases using the mRNA expression data. This process
provided a quantitative measure to describe the overall response of
the human system to a given disease. Subsequently, we used these
measures to identify 138 significant associations between diseases.
We also discovered functional modules that are common to at least
half of the diseases representing a common ‘‘disease-state’’
signature. These common disease-state modules were not only
significantly enriched for genes that were known drugs targets, but
their corresponding drugs were known to treat significantly more
diseases than expected by chance highlighting their importance as
therapeutic opportunities.
Results/Discussion
Protein complexes and pathways are accountable for most
processes in the cell. Accordingly, we can gauge the response of a
cell system to a certain perturbation (such as disease) by the
measuring changes in the expression levels of various functional
modules of the system. To this end, we first generated a catalog of
4,620 functional modules by querying the large-scale human
protein interaction network (see Methods). We then collected the
mRNA expression arrays associated with each disease from the
Gene Expression Omnibus (GEO) [11]. After several rounds of
filtering the gene expression data for accuracy, reliability, and
experimental context, we had microarrays representing 54 human
diseases (see Methods and Table S1). Next, we combined the gene
expression data and the 4,620 functional modules to generate a
Module Response Score (MRS) for each module in each disease-
state representing its activity level (see Methods). Specifically,
positive MRS values correspond to modules that are up-regulated
and negative MRS values identify modules that are down-
regulated in the disease-state as compared to the control (healthy).
Figure 1 gives an overview of the process to compute the MRS
values for a given disease. In the end, we generated a matrix
containing the MRS values for each module in each of the 54
diseases considered in this study. The relationships between
different diseases were then ascertained by the Partial Spearman
correlation coefficient of their MRS values (see Methods and
Figure S1). Specifically, we calculated the Spearman correlation
between two diseases conditioned on the responses of the
functional modules in their respective control samples. The use
of the Partial Spearman correlation coefficient instead of the
generic Spearman correlation coefficient not only provided a
quantitative metric to assess disease similarity but also explicitly
factored out the possible dependencies between different gene-
expression experiments due to their underlying tissue or cell types.
Figure 2(A) is the hierarchical clustering of diseases based on the
correlations generated above. To assign significance to these
associations, we randomized the gene to module assignments as
well as the control and disease labels 100 times to generate a
background distribution of disease correlations (see Methods). We
then selected only those disease correlations that passed the p-value
threshold of 0.01 (FDR=10.37%) resulting in 138 significant
disease-disease similarity relationships. Immediately, we see that
many expected disease associations such as the brain disorders like
Alzheimer’s disease, Bipolar disorder and Schizophrenia are
pooled together in one sub-branch. We also see many novel and
hitherto unknown significant correlations such as the similarity
between uterine leiomyoma and lung cancer. We also created a
network representation to display all the 138 significant disease
correlations (Figure 2(B)). In this network, the nodes are diseases,
while the thickness of the edges between two diseases represents
their strength of correlation. This abstraction allows us to pick
additional significant disease associations that were missing in the
hierarchical clustering. For example, Crohn’s disease and Malaria
share a significant disease correlation. A listing of all the significant
disease correlations is provided in Table S2.
Although the 54 diseases considered in this study cover many
categories of diseases ranging from cancers to cardiomyopathies,
some categories of diseases such as cancer are over-represented as
opposed to others such as infectious diseases. Ideally, we would like
to explicitly correct for this bias by down-weighing over-
represented classes. However, the principle behind organizing
diseases into categories such as cancers, infectious diseases and
others is not the same. For instance, diseases are classified as
cancers if their underlying pathology consists of a group of cells
that show uncontrolled growth, invasion of nearby cells and
metastasis. On the other hand, infectious diseases relates to
diseases which are caused by pathogens and have the potential to
spread from person to person. Lack of a common organization
scheme prevents us from explicitly correcting for the observed
over-representation. Moreover, there is considerable heterogeneity
even among diseases of the same category. For instance, the
category of cancers covers a wide variety of diseases affecting
Author Summary
Many human diseases are related to each other through
shared causes or even shared pathology. Knowledge of
these relationships has long been exploited to treat similar
diseases with the same therapies. However, most of the
traditional approaches to discover these relationships have
depended on subjective measures, such as similarity in
symptoms, or incomplete knowledge, such as genes with
mutations. Here we present the first approach integrating
high-throughput datasets such as mRNA expression and
large-scale protein-protein interaction networks to discov-
er human disease relationships in a systematic and
quantitative way. We discover 138 significant pathological
similarities between 54 human diseases ranging from lung
cancer, schizophrenia, and malaria. We also discovered a
set of common pathways and processes within the cell
that are dysregulated in at least half of the diseases. We
infer that these processes correspond to a common
response of the human system to a disease state.
Interestingly, we find that many of the proteins in these
pathways are already known to be targets of existing
drugs. In fact, the drugs corresponding to these proteins
are known to treat significantly more diseases than
expected by chance highlighting the importance of these
common molecular pathological pathways as prime
therapeutic opportunities.
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PLoS Computational Biology | www.ploscompbiol.org 2 February 2010 | Volume 6 | Issue 2 | e1000662Figure 1. Overview of the process to generate the module response scores for each disease. (A) Normalization of the gene expression
matrices through a Z-score transformation. In the gene expression matrix for a given disease k, gij represents the expression value of gene i in sample
j, gj corresponds to the whole set of gene expression values for a given sample j (j
th column) and zij corresponds to the z-score transformed gene
expression value of gene i sample j. (B) Response score of a gene in a given disease. The response score of gene i in a disease k is the t-test statistic
between the disease and control sample values for that gene. This score is represented as Sik. (C) Module response score calculation. The Module
Response Score (MRS) of a given module i in a given disease k (Mik) is average of the response scores of its component genes. Detailed description of
this process is provided in the Methods section.
doi:10.1371/journal.pcbi.1000662.g001
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PLoS Computational Biology | www.ploscompbiol.org 3 February 2010 | Volume 6 | Issue 2 | e1000662Figure 2. Significant disease-disease similarities. (A) Hierarchical clustering of the disease correlations. The distance between two diseases was
defined to be (1-correlation coefficient) of the two diseases. The tree was constructed using the average method of hierarchical clustering. The red
line corresponds to a p-value of 0.01 and FDR of 10.37% and, disease correlations below this line are considered significant. The different colors
represent the various categories of significant disease correlations. (B) The network of all the 138 significant disease correlations. The colors
correspond to significant disease correlation categories in (A). The nodes colored in grey are not marked in (A).
doi:10.1371/journal.pcbi.1000662.g002
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causes ranging from mutations caused by chemical carcinogens to
bacterial and viral infection. This heterogeneity is seen even at the
transcriptional level [12]. We also have observed this heterogene-
ity in the results of our study as all the 17 cancers considered in our
analysis did not cluster together (Figure 2(A)). By combining both
mRNA expression and protein interaction data, we are providing
one of the first ways to compare and classify diseases systemat-
ically. The common organizing principle here is the molecular
pathology of a given disease.
At the outset, we explored the genetic basis of the diseases in our
study to explain and validate the observed disease correlations.
Specifically, we aimed to test the hypothesis that diseases which
are significantly associated through the MRS-based correlation
coefficient also significantly shared disease genes. For this purpose,
we collected a list of genes known to be associated with diseases,
hereinafter as the Disease Gene List (see Methods). We found
known gene variants associated with only 31 of the 54 diseases in
our study resulting in an overall total of 465 possible pair-wise
disease comparisons. A pair of diseases was considered to
significantly share disease genes only if the Hypergeometric p-
value of the overlap was less than 0.01. Eighty-two of the overall
465 comparisons significantly shared disease genes. On the other
hand, only 73 of the 465 disease pairs were significantly associated
using the MRS-based correlation coefficient. This gives rise to a
contingency table as shown in Table 1 with a one-sided Fisher’s
Exact Test p-value of 0.033. It suggests that the genetic similarity
between diseases significantly contributes to the molecular
pathological disease similarity observed in this study. Lack of a
strong p-value might be explained by the fact that the number of
known disease genes are much higher for well-studied diseases like
Schizophrenia (345 genes) as opposed to less well-studied diseases
like Mixed hyperlipidemia (4 genes). Mapping of genes to diseases
was also hindered due to fact that we used a very strict vocabulary
to define diseases (see Methods). Finally, this result might also
allude to the role of environment in disease causation and
similarity. A few of the significant disease correlations which also
significantly shared disease genes is provided in Table 2 and the
complete list is provided in Table S3.
In order to further understand the biology behind the
observed disease correlations, we examined some of their
underlying functional modules. First, we analyzed the sub-branch
of brain disorders, Alzheimer’s disease (ALZ), Bipolar disorder
(BIP), Schizophrenia (SCHZ), and Glioblastoma (GLIO), in the
hierarchical representation of the disease correlations (Figure 2(A))
in more detail. Figure 3(A.i) corresponds to the synaptic vesicle
and was one of most down-regulated modules in all four diseases
(second lowest average MRS value). This module is a secretory
organelle that stores neurotransmitters and releases them into the
synapse. Loss of synaptic functions and more specifically,
decreased expression of synaptic vesicle proteins such as SNAP-
25 is one of the main effects of ALZ [13,14]. Decreased synaptic
function has also been observed for both BIP and SCHZ [15,16].
In particular, the levels of protein SNAP-25 was shown to be
reduced in both BIP and SCHZ [17]. The function of this module
in GLIO is still to be explored. Uterine leiomyomas (UTL) are
benign tumors affecting the uterus. As shown in Figure 2(A), UTL
shares a strong correlation with lung cancers. Figure 3(A.ii)
corresponds to the DNA repair pathway which had the highest
average MRS value for the three diseases. Polymorphisms in the
genes involved in the DNA repair pathway such as PCNA, POLB
have been associated with increased risk of lung cancer [18].
Moreover, the Arg399Glu allele of the XRCC1 gene has been
shown to be a risk factor for lung adenocarcinoma [19] and lung
squamous cell carcinoma [20]. Surprisingly, the same Arg399Glu
polymorphism in the XRCC1 gene has also been associated with
an increased risk of UTLs [21] giving causal genetic evidence for
the correlation we observed between the diseases using micro-
array-based molecular pathological measurements.
Knowledge of a comprehensive disease-similarity tree (net-
work) based on molecular data could possibly be used in finding
new uses for existing drugs. Similar diseases share similar
molecular phenotypes and could potentially be treated by similar
drugs. To explore this avenue, we collected a list of drugs, their
corresponding target genes and the diseases they are known to
treat (US FDA approved indications) or off-label uses. This
information was obtained from the RxNorm from National
Library of Medicine [22], DrugBank [23], National Drug File
Reference Terminology (ND-FRT) [24] and MicroMedex [25].
Overall, 17 of the 138 significant disease correlations shared at
least one drug in common and 14 of them had a significant
Hypergeometric p-value less than 0.01 (Table 3, Table S4). For
instance, we found that the FDA approved drug Flouroucil, used
to treat Actinic keratosis, has been shown to have positive
indications for treating Malignant tumor of the colon [25].
Similarly, the drug Doxorubicin is FDA approved to treat both
Urothelial carcinoma and Acute myeloid leukemia [25]. This
number is a conservative estimate as the list of drugs used here is
incomplete. Moreover, we used a very specific vocabulary to
define diseases (see Methods) and accordingly mapped drugs to
them. For instance, we found many drugs treating lung cancer;
however in many cases, our combi n e dk n o w l e d g eb a s ed o e s n ’ t
specify whether the cancer was an adenocarcinoma or a
squamous cell carcinoma. In those cases, we excluded the drug
from our consideration. A caveat to this approach is that drugs
can be shared between diseases mainly because the correspond-
ing diseases belong to the same category. For instance, drugs can
be shared between two cancers etc. As a result, it is difficult to
differentiate whether two diseases shared drugs due to the
similarity in their molecular pathology or due to their underlying
disease type. Moreover, the chemical similarity between drugs
can also affect the reported p-values.
Table 1. Contingency table to evaluate the hypothesis that significant disease correlations also significantly shared disease genes.
Number of disease pairs MRS-based disease correlations
Significant Not significant Totals
Shared disease genes Significant 19 63 82
Not significant 54 329 383
Totals 73 392 465
We performed a one-sided Fisher’s Exact Test on this table giving a p-value of 0.033.
doi:10.1371/journal.pcbi.1000662.t001
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response of the cell system to a disease is that we can use this
methodology to find modules that are generally dysregulated
(activated or repressed) in the disease-state. In other words, we
used the MRS values to characterize a common ‘‘signature’’ across
disease-states. In order to generate the set of modules that are
commonly dysregulated in the 54 diseases considered in this study,
we used a two-fold approach. Firstly, a module was selected if the
median of its absolute MRS values across all diseases was
significantly higher than expected at random. We generated a
random background distribution of median scores by shuffling the
gene to module assignments (see Methods). Overall, at a p-value of
0.01 and associated FDR of 16.15%, we selected 286 modules. We
then filtered the above set of 286 modules to only include those
modules which were significantly differentially expressed in many
diseases. A module was determined to be significantly differentially
expressed in a given disease if the absolute value of its MRS was
above 1.5 (p-value=0.028). Finally, we selected 59 modules that
were significantly differentially expressed in 20 or more diseases as
the common disease state signature. These modules were not only
dysregulated in at least half of the diseases each but were also
significantly differentially expressed in more than 20 diseases.
Moreover, these 59 modules taken together were dysregulated in
45 of the 54 diseases in our study. Figure S2 shows the combined
illustration of all the 59 modules. They were mainly enriched for
the functions of immune system response (p-value=6E-70) and
DNA repair (p-value=4.1E-30). A representative sample of 7
modules is shown in Figure 3(B.iii–vii).
We investigated the 59 modules further by searching for known
drug target genes/proteins. We obtained the list of drugs and their
corresponding targets from the DrugBank database [23]. Overall,
70 genes/proteins within the 59 signature pathways were
identified as targets of known drugs giving a Hypergeometric p-
value of 1.8E-11. Thus, the set of the signature modules was
significantly enriched for drug target genes compared to that
expected by chance. We then predicted that other genes/proteins
in these modules would also serve as prime candidates for
designing new drugs. Most existing drug target genes usually fall
into a comparatively small set of gene families such as G protein
coupled receptors, serine proteases etc [26]. Hence, new drug
targets can be found by exploring other members of the protein
families of the existing drug targets. We explored the 59 signature
modules for genes which belonged to the same protein families as
known drug target genes. For that purpose, we obtained a list of
genes and their corresponding families and sub-families from the
PANTHER database [27]. Overall, we found 241 genes among a
total of 450 genes in the signature modules sharing the same
protein families as the known drug target genes compared to a
total of only 3,520 such genes in the whole human PPI giving a
Hypergeometric p-value of 1.47E-12. Therefore, the 59 signature
modules were also significantly enriched for druggable genes.
Further, we also counted the number of distinct diseases that are
known to be treated by the drugs corresponding to each of the 70
known drug targets. We observed that drugs targeting these 70
genes are known to treat an average of 65 diseases each compared
to an average of ,42 diseases for all known drug targets (p-
value=0.02). These results provide evidence that the genes in the
signature modules are more likely to be good drug targets and
drugs that target these proteins are more likely to treat many
diseases. Yildirim et al. [28] showed that most drugs seemed to be
palliative and only cured the symptoms of the diseases rather than
the diseases themselves. Therefore, the enrichment for drug target
genes which treat many diseases might be due to the shared
symptoms of the diseases.
In summary, this study demonstrates the value of an integrated
approach in revealing disease relationships and the resultant
opportunities for therapeutic applications. Looking forward, we
aim to incorporate more gene expression data from GEO and
other similar repositories, and expand the set of diseases in our
disease-similarity network.
Methods
Gene expression dataset
The gene expression data used in this analysis was obtained
from the NCBI Gene Expression Omnibus (GEO) [11]. In this
study, we restricted to using only those microarrays that were
curated and reported in the GEO Datasets (or GDS). We selected
for microarrays that were assigned to human disease conditions.
These assignments were made by the method explained in Butte
et al. [29]. Briefly, the experimental context of a collection of
microarrays from GEO (or GEO Series, GSE) can be obtained
from the Medical Subject Headings (MeSH) [9] terms associated
with the records of corresponding publications in PUBMED.
Subsequently, the MeSH terms were connected to disease
concepts using the Unified Medical Language System (UMLS)
[30]. The GDS curation provided more details such as the tissue
or biological substance from which the samples were derived. We
only included those GSEs in which both disease as well as their
corresponding control condition was measured in the same tissue
(cell type) in the same experiment, using a previously described
method [31]. We also manually selected for GSEs in which the
control was a healthy sample. Further, we removed all GSEs that
included time-series data to avoid complications arising due to
temporal changes in gene expression. For consistency, we also
restricted the GSEs to only those arrays which used Affymetrix
Gene Chip Human Genome U133 Array Set HG-U133A or U95
Version 2 platforms, which are among the most commonly used
Table 2. Genetic similarity between significant disease correlations.
Disease 1 Disease 2 Correlation
# shared disease
genes
Disease 1
genes
Disease 2
genes
Hypergeometric p-
value
Bipolar disorder Schizophrenia 0.524 98 145 345 1.6E-23
Endometriosis Malignant neoplasm of prostate 0.356 28 56 173 6.69E-11
Crohn’s disease Malaria 0.381 23 120 63 2.86E-9
This table shows only 3 of the 19 disease correlations significantly sharing at least one disease gene. The complete list is in Table S3. The ‘‘correlation’’ column indicates
the calculated MRS-based correlation between the respective diseases. The number of genes whose variants are associated with any given disease was obtained from
the Disease Gene List. We calculated the hypergeometric p-value by estimating the probability of seeing the observed overlap or more by chance accounting for the
total number of disease genes present in our dataset (N=2,104).
doi:10.1371/journal.pcbi.1000662.t002
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PLoS Computational Biology | www.ploscompbiol.org 6 February 2010 | Volume 6 | Issue 2 | e1000662Figure 3. Underlying functional modules. (A) Two representative samples of functional modules. (i) The synaptic vesicle module is one of the
most down-regulated modules among set of brain disorders: Alzheimer’s disease, Bipolar disorder, Schizophrenia and Glioblastoma. (ii) The DNA
repair module is one of the most up-regulated modules among the lung cancers and Uterine leioyomyoma. The colors of the nodes represent their
average gene expression in their corresponding diseases. The genes marked with a red star next to them are genes with known variants associated
with disease (see methods). (B) A representative sample of common disease ‘‘signature’’ modules. The genes colored in orange correspond to known
drug targets. The functions for the modules were obtained by the functional enrichment tool of the DAVID database [45].
doi:10.1371/journal.pcbi.1000662.g003
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described [32]. As both of these platforms have shared probe-sets,
the bias of the platform used on the overall analysis would be
reduced considerably. We subsequently selected GSEs that had at
least two disease samples and two control samples. GEO contains
some experiments (GSEs) that have gene expression measure-
ments for more than one disease but share the same control
measurements. Such measurements might induce correlations
between their component diseases, which are not necessarily
biological. Thus, to avoid bias, in all such cases, we included only
one representative disease for each set of control samples in
contrast to Hu et al. [10]. This entire process yielded 54 diseases for
our final analysis.
Protein interaction data
The protein-protein interaction (PPI) data for human was
obtained from the Human Protein Reference Database (HPRD)
[33]. This database contains PPI obtained from the two high-
throughput yeast two-hybrid experiments [34,35] as well as
through literature curation. Further, HPRD contains the maxi-
mum number of PPI of any of publicly available literature-derived
databases for human PPI [36]. We filtered the PPI for human
proteins that had a corresponding Entrez Gene ID, yielding
34,998 unique protein interactions spanning 9303 proteins in
human. Previously, Sharan et al. [37] presented the PathBLAST
family of network alignment tools. Briefly, these methods help
identify conserved modules between protein networks of two (or
more) species. Suthram et al. [38] also used it effectively to identify
dense subnetworks corresponding to functional modules within a
protein network of a single species. Applying the same approach
here, we identified 4,620 functional modules in the human PPI
network.
Module Response Score (MRS) generation
First, we normalized the gene expression data in each
microarray sample (disease state or control) using the Z-score
transformation. This transformation allows for the direct compar-
ison of gene expression values across various microarray samples
and diseases. Next, we computed the activity level of a gene i in
disease k as the t-test statistic (Sik) of its Z-transformed score
between the disease and the control samples for each disease. In
cases where there was more than one experiment (or GEO Series)
for a given disease, we employed a meta-analysis technique using
linear regression to obtain a combined t-test statistic. This
approach takes into account the variations between different
experiments in the calculation of the gene activity score (Sik) (see
section below). Finally, the module response score (Mik) for each
module i in a disease k is assigned to be the mean of the gene
activity scores (Sik) of its component genes. In the end, we obtained
a vector of module response scores (Mik) for each disease.
Combined t-test statistic for multiple experiments
The t-test statistic between two conditions can be represented
using linear regression. For instance, let Yi and Xi be gene
expression values and disease state (disease has a value of 1 and
control a value of 0), respectively. Then, we have a linear
regression model as follows:
Yi~b0zb1Xi
where b0 and b1 are the parameters of the model. The t-test
statistic when estimating the value of b1 is the same as the standard
t-test statistic between disease and control states. The advantage of
the linear regression model is that we can add more terms to the
model to account for other sources of variation such as the
experiment number. In the present work, we expanded on the
above model as follows:
Yi~b0zb1Xiza1I1
i za2I2
i z   zakIk
i z   zan{1In{1
i
where n is the number of different experiments for a given disease
and, Ik
i is an indicator variable which is 1 if the i’
th gene expression
measurement is from the experiment number k. Again, the b
0s and
a0s are the parameters of the model which need to be estimated.
The addition of the new terms allows for explicitly accounting for
the effect of the experiment on the gene expression value. This
approach is similar to a mixed effects model for adjusting for the
within-experiment dependencies, but is more aggressive in
removing such effects. Consequently, the t-test statistic in the
estimation of b1 will now be a combined metric for the different
studies.
Partial correlation
The partial correlation coefficient gives the correlation between
two variables, say x and y, keeping a third variable, z, constant.
This method tries to measure the similarity between x and y, over
and above that caused by their common dependency on z. The
partial correlation can be calculated as follows:
cxy:z~
cxy{cxzcyz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1{c2
xz)
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1{c2
yz
q
)
The above formula can be expanded to condition on two
variables as follows:
cxy:zw~
cxy:z{cxw:zcyw:z
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1{c2
xw:z)
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1{c2
yw:z
q
)
Table 3. Shared drugs among significant disease correlations.
Disease 1 Disease 2 Correlation # shared Drugs Drugs 1 Drugs 2
Hypergeometric p-
value
Actinic keratosis Malignant tumor of colon 0.428 1 9 13 4.40E-04
Bipolar disorder Schizophrenia 0.524 16 37 106 3.35E-17
Acute myeloid leukemia Urothelial carcinoma 0.496 2 31 10 7.00E-05
This table shows only 3 of the 14 significant disease correlations that significantly shared at least one drug. The complete list is in Table S4. The ‘‘correlation’’ column
indicates the calculated correlation between the respective diseases. We calculated the hypergeometric p-value by estimating probability of seeing the observed
overlap or more by chance accounting for the total number of drugs in our knowledge base (N=3,536).
doi:10.1371/journal.pcbi.1000662.t003
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between two diseases conditioned on the responses of the
functional modules in their respective control samples. The
response of a functional module in the control samples for a
given disease was calculated as the mean of the z-transformed
scores of its component genes. As a result, the Partial Spearman
correlation coefficient provided a quantitative metric to assess
disease similarity and also explicitly factored out the possible
dependencies between different gene-expression experiments due
to their underlying tissue or cell types [39]. Our approach is
consistent with the findings by Dudley et al. [40] that the disease
signal in the GEO datasets is stronger than the tissue signal and
hence, implying that the observed disease correlations reflect true
biology. We used the R script provided by Kim et al. [41] for
calculating the Partial Spearman correlation between two diseases.
Randomization procedure
To assign significance to the observed disease correlations, we
created a background distribution of disease correlations
expected at random. First, we randomized the gene to module
assignments. We envisioned the gene to module assignments as a
bi-partite graph (Figure S3) where there exists a link between a
gene and a module if that gene is a member of that module. We
then randomized the graph by randomly swapping links. This
process preserved the number of modules, the number of genes
assigned to a module as well as the number of modules a given
genebelongsto. Next, we also shuffled the disease and thecontrol
sample labels. We then calculated the MRS values for the
modules using the randomized data and computed the corre-
sponding disease correlations. Finally, we repeated the whole
process 100 times to create a background distribution of disease
correlations.
Disease gene list generation
We built a comprehensive disease-associated gene database,
referred to as the Disease Gene List, by collecting genes known to
be associated with various diseases from literature curation and
large databases. In particular, we first curated 37,953 disease
Single Nucleotide Polymorphism (SNP) associations from 2,679
papers, mapping 10,167 specific SNPs from the SNP Database
(dbSNP) to 748 diseases and phenotypes. We then annotated each
SNP with its corresponding gene(s) using dbSNP (Chen and Butte,
unpublished data). Next, we extracted genes that are significantly
associated with diseases in Genetic Association Database (GAD)
[42]. These consisted of associations that were reported to be
positive at least once. We also collected genes that are associated
with disorders in the Online Mendelian Inheritance in Man
(OMIM) [5]. Lastly, we retrieved genes that are associated with
diseases in the professional version of Human Gene Mutation
Database (HGMD) [43]. Finally, we combined disease genes
obtained from the above four different sources by relating them to
Entrez gene IDs and removing outdated Gene IDs using AILUN
[32].
Module visualization
The module figures in the paper were drawn using the
Cytoscape software [44].
Supporting Information
Figure S1 Schematic of the calculation of the Partial Spearman
correlation between two diseases.
Found at: doi:10.1371/journal.pcbi.1000662.s001 (0.49 MB EPS)
Figure S2 Combined representation of the 59 common disease-
state ‘‘signature’’ modules. The genes marked in orange are known
drug target genes.
Found at: doi:10.1371/journal.pcbi.1000662.s002 (2.35 MB EPS)
Figure S3 Graphical representation of the genes to modules
assignments.
Found at: doi:10.1371/journal.pcbi.1000662.s003 (0.40 MB EPS)
Table S1 List of the 54 diseases considered in this study.
Found at: doi:10.1371/journal.pcbi.1000662.s004 (0.02 MB XLS)
Table S2 List of the 138 significant disease correlations.
Found at: doi:10.1371/journal.pcbi.1000662.s005 (0.03 MB XLS)
Table S3 Genetic similarity between significant disease correla-
tions. This table shows the 19 disease correlations significantly
sharing at least one disease gene. The number of genes whose
variants are associated with any given disease was obtained from
the Disease Gene List. We calculated the hypergeometric p-value
by estimating the probability of seeing the observed overlap or
more by chance accounting for the total number of disease genes
present in our dataset (N=2,104).
Found at: doi:10.1371/journal.pcbi.1000662.s006 (0.02 MB XLS)
Table S4 This table shows the 14 significant disease correlations
that significantly shared at least one drug. We calculated the
hypergeometric p-value by estimating probability of seeing the
observed overlap or more by chance accounting for the total
number of drugs in our knowledge base (N=3,536).
Found at: doi:10.1371/journal.pcbi.1000662.s007 (0.02 MB XLS)
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